Glycyl Proline

Glycyl Proline

SCHEMBL6660425

NCC(=O)N1CCC[C@H]1C(=O)O.O=C(O)C(F)(F)F

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE P12821 7/20 0.53
DPP4 P27487 1/20 0.47
PREP P48147 1/20 0.47
FAP Q12884 1/20 0.47
DPP8 Q6V1X1 1/20 0.47
DPP9 Q86TI2 1/20 0.47
LMNA P02545 2/20 0.47
HSD17B10 Q99714 2/20 0.47
CYP2C19 P33261 1/20 0.47
CHRM3 P20309 1/20 0.45
MVD P53602 2/20 0.45
REN P00797 2/20 0.43
KDM4E B2RXH2 1/20 0.43
F2 P00734 1/20 0.43
LTA4H P09960 1/20 0.43
MAPT P10636 1/20 0.43
PEPD P12955 1/20 0.43
ALOX15 P16050 1/20 0.43
PTGS1 P23219 1/20 0.43
HTR2A P28223 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glycyl Proline SCHEMBL30051559 0.90 ACE (0.62) ACEDPP4PREPFAPDPP8
Glycyl Proline SCHEMBL155067 0.90 ACE (0.62) ACEDPP4PREPFAPDPP8
Glycyl Proline SCHEMBL155066 0.90 ACE (0.62) ACEDPP4PREPFAPDPP8
Glycyl Proline SCHEMBL4167998 0.89 ACE (0.60) ACEDPP4PREPFAPDPP8
Glycyl Proline SCHEMBL4168006 0.89 ACE (0.60) ACEDPP4PREPFAPDPP8
Glycyl Proline SCHEMBL28116179 0.87 ACE (0.58) ACEDPP4PREPFAPDPP8
Glycyl Proline SCHEMBL28116177 0.87 ACE (0.58) ACEDPP4PREPFAPDPP8
SCHEMBL31364129 0.85 ACE (0.56) ACEDPP4PREPFAPDPP8
SCHEMBL10656884 0.84 ACE (0.55) ACEDPP4PREPFAPDPP8
SCHEMBL29777459 0.84 ACE (0.55) ACEDPP4PREPFAPDPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1087935-B1 ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS BTG INT LTD (GB) 2004-08-18 EP disclosed
US-20030203975-A1 Anti-cancer agents BTG INTERNATIONAL LIMITED (GB) 2003-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203975-A1 Anti-cancer agents TOP2B, TOP2A, TOP1 ACE 1827/4885DPP4 3236/4885PREP 1647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.